Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25967729 | 0.92 | OPRD1 (0.45) | OPRD1L3MBTL3L3MBTL1L3MBTL4MBTD1 | |
| SCHEMBL25965344 | 0.83 | USP30 (0.53) | — | |
| SCHEMBL25965350 | 0.79 | LIPG (0.36) | L3MBTL3ALDH1A1NPY5RCCR5 | |
| SCHEMBL25967727 | 0.78 | MEN1 (0.51) | — | |
| SCHEMBL16391135 | 0.76 | CASP6 (0.44) | L3MBTL3NPY5R | |
| SCHEMBL16698134 | 0.76 | CASP6 (0.44) | L3MBTL3NPY5R | |
| SCHEMBL16698136 | 0.76 | CASP6 (0.44) | L3MBTL3NPY5R | |
| SCHEMBL1419786 | 0.75 | ALDH1A1 (0.39) | L3MBTL3MBTD1ALDH1A1 | |
| SCHEMBL25356633 | 0.75 | KDM1A (0.48) | L3MBTL3L3MBTL1ALDH1A1NPY5R | |
| SCHEMBL14242799 | 0.74 | ALDH1A1 (0.38) | L3MBTL3MBTD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | OPRD1 4575/4885L3MBTL3 4811/4885L3MBTL1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.